miRNAs from blood serum as an early diagnostic biomarker for Parkinson’s disease: A study in an animal model
Objective: This work aims to elucidate miRNA-based biomarkers for the early stages of Parkinson`s Disease diagnosis in a chemically induced PD rat model. Background: The…Dopaminergic neuronal cell therapy for Parkinson’s Disease: results from a phase 1 study of Bemdaneprocel
Objective: This first-in-human Phase 1 study aims to assess the safety, tolerability, clinical efficacy, and functional imaging measures of bemdaneprocel in subjects with PD. Background:…Targeting autophagy to identify novel modulators of Parkinson’s disease using midbrain organoids
Objective: Natural compound libraries are a great source of new chemical molecules that could restore the altered phenotypes in patient derived cells. The objective of…The impact on religiosity following Deep Brain Stimulation (DBS) in patients with Essential Tremor (ET) and Parkinson’s Disease (PD)
Objective: To determine the impact of DBS on religiosity. Background: Religiosity has been mapped to various brain networks1, 2, and transcranial magnetic stimulation has transiently…Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.
Objective: To evaluate the pathophysiology of the midbrain dopaminergic neurons (mDAN) derived from LRRK2 I1371V PD patient-iPSCs leading to susceptibility to oxidative stress. Background: Studies…GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.
Objective: To investigate the effect of the structurally targeted allosteric regulator GT-02287 on rotenone-induced neurotoxic effects in a Parkinson’s disease animal model. Background: Mutations in…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease
Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs
Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »